{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:15Z","timestamp":1792432035119,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.11.008","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T15:42:11Z","timestamp":1670427731000},"page":"564-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-6360","authenticated-orcid":false,"given":"Renske","family":"van der Meer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-7794","authenticated-orcid":false,"given":"Erik B","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot N","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M","family":"Paalvast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C J M","family":"van Rossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry G M","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.11.008_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2022.11.008_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.11.008_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.11.008_bib0004","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013Ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.11.008_bib0005","unstructured":"Kalydeco. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/kalydeco-epar-product-information_en.pdf."},{"key":"10.1016\/j.jcf.2022.11.008_bib0006","unstructured":"Orkambi. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/orkambi-epar-product-information_en.pdf."},{"key":"10.1016\/j.jcf.2022.11.008_bib0007","unstructured":"Kaftrio. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/kaftrio-epar-product-information_en.pdf."},{"key":"10.1016\/j.jcf.2022.11.008_bib0008","unstructured":"Symkevi. Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/symkevi-epar-product-information_en.pdf."},{"issue":"5","key":"10.1016\/j.jcf.2022.11.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.04.005","article-title":"Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls","author":"van der Meer","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.11.008_bib0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/ajcn\/67.5.912","article-title":"Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts","volume":"67","author":"Benabdeslam","year":"1998","journal-title":"Am J Clin Nutr"},{"issue":"21","key":"10.1016\/j.jcf.2022.11.008_bib0011","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.11.008_bib0012","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jcf.2022.11.008_bib0013","first-page":"1383","article-title":"Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment","volume":"90","author":"Bruno","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jcf.2022.11.008_bib0014","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","author":"Wright","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jcf.2022.11.008_bib0015","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2022.11.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10.1016\/j.jcf.2022.11.008_bib0017","first-page":"E16","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"4","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2022.11.008_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MPG.0000000000001446","article-title":"Causal evaluation of acute recurrent and chronic pancreatitis in children: consensus from the Insppire group","volume":"64","author":"Gariepy","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2022.11.008_bib0019","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","article-title":"Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series","volume":"66","author":"Carrion","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2022.11.008_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:29Z","timestamp":1761601709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322014205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199322014205"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.11.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}